Drug Profile
Research programme: angiogenesis inhibitors - Celltech/Johnson & Johnson
Alternative Names: JNJ-17029259Latest Information Update: 21 Sep 2007
Price :
$50
*
At a glance
- Originator Celltech R&D; Johnson & Johnson
- Developer Celltech R&D
- Class
- Mechanism of Action Angiogenesis inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Diabetic retinopathy
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
- 04 Apr 2003 No development reported - Preclinical for Diabetic retinopathy in United Kingdom (unspecified route)
- 02 Aug 2001 Preclinical development for Diabetic retinopathy in United Kingdom (Unknown route)